Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Academic Article uri icon

Overview

MeSH

  • Aged
  • Controlled Clinical Trials as Topic
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piperazines
  • Purines
  • Reproducibility of Results
  • Severity of Illness Index
  • Sildenafil Citrate
  • Sulfones
  • Vasodilator Agents

MeSH Major

  • Dyspnea
  • Exercise Test
  • Idiopathic Pulmonary Fibrosis
  • Quality of Life
  • Research Design
  • Surveys and Questionnaires
  • Walking

abstract

  • Dyspnea is a hallmark symptom of idiopathic pulmonary fibrosis (IPF), and dyspnea induced physical activity limitation is a prominent driver of quality of life impairment among IPF patients. We examined response data for the 21 physical activity items (the first 21 of 24) from the University of California San Diego Shortness of Breath Questionnaire (UCSD) collected at baseline in a recently conducted IPF trial. We used Rasch analysis and hypothesis testing with conventional statistical methodology to achieve three objectives: 1) to examine the items to identify the one characteristic that distinguishes one from another; 2) to asses these items for their ability to measure dyspnea severity in IPF; 3) to use the items to develop a dyspnea ruler. The sample comprised 178 subjects. The 21 items fit the Rasch model. There was very strong correlation between Rasch item severity and their metabolic equivalents (METS) values (r = -0.86, p < 0.0001). With the sample stratified on scores from the 21 items, there were significant between group differences in FVC%, DLCO% and distance walked during the six-minute walk test. The dyspnea ruler can be used to put dyspnea levels in a more easily understood clinical context. The first 21 items from the UCSD compose a unidimensional dyspnea-with-activity scale and are both sensibly ordered and distinguished from each other by their METS values. These 21 items can be used confidently to formulate clinically-relevant inferences about IPF patients and should be considered for use as a meaningful endpoint in IPF research. Copyright © 2013 Elsevier Ltd. All rights reserved.

authors

publication date

  • January 2014

has subject area

  • Aged
  • Controlled Clinical Trials as Topic
  • Dyspnea
  • Exercise Test
  • Female
  • Humans
  • Idiopathic Pulmonary Fibrosis
  • Male
  • Middle Aged
  • Piperazines
  • Purines
  • Quality of Life
  • Reproducibility of Results
  • Research Design
  • Severity of Illness Index
  • Sildenafil Citrate
  • Sulfones
  • Surveys and Questionnaires
  • Vasodilator Agents
  • Walking

Research

keywords

  • Journal Article
  • Validation Studies

Identity

Language

  • eng

PubMed Central ID

  • PMC3951298

Digital Object Identifier (DOI)

  • 10.1016/j.rmed.2013.12.009

PubMed ID

  • 24388667

Additional Document Info

start page

  • 181

end page

  • 188

volume

  • 108

number

  • 1